市場調査レポート
商品コード
1125207

後天性フォンヴィレブランド病(AvWD)治療の世界市場 - 成長、将来の見通し、競合分析(2022年~2030年)

Acquired vWD Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
後天性フォンヴィレブランド病(AvWD)治療の世界市場 - 成長、将来の見通し、競合分析(2022年~2030年)
出版日: 2022年08月17日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の後天性フォンヴィレブランド病(AvWD)治療の市場規模は、2022年~2030年の予測期間中にCAGRで5.86%の成長が予測されています。後天性フォンヴィレブランド病とそれに関連する治療についての世界各国の政府の認識が高まり、市場に対する需要が高まっています。

当レポートでは、世界の後天性フォンヴィレブランド病(AvWD)治療市場について調査分析し、市場力学、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場スナップショット:世界の後天性フォンヴィレブランド病(AvWD)治療市場
  • 世界の後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2021年)
  • 世界の後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2021年)
  • 世界の後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2021年)
  • 世界の後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2021年)
  • 世界の後天性フォンヴィレブランド病(AvWD)治療市場:地域別(2021年)
  • COVID-19の影響
  • 魅力的な投資提案:地域別(2021年)
  • 競合分析
    • 主な後天性フォンヴィレブランド病(AvWD)治療市場ベンダーの市場ポジショニング
    • 後天性フォンヴィレブランド病(AvWD)治療市場ベンダーが採用する戦略
    • 主な業界の戦略
    • 階層分析(2021年対2030年)
  • 主な購入基準
  • 主な症例報告
  • シナリオ分析
    • 楽観的な推計と分析
    • 現実的な推計と分析
    • 悲観的な推計と分析
  • 市場プロファイリング
  • 販売・マーケティング計画
  • 主な市場の結論
  • 戦略的推奨事項

第3章 後天性フォンヴィレブランド病(AvWD)治療市場:事業の見通しと市場力学

  • イントロダクション
  • 世界の後天性フォンヴィレブランド病(AvWD)治療の市場金額(2020年~2030年)
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響の分析
  • シーソー分析
  • ポーターのファイブフォースモデル
  • PESTEL分析
  • ヘプタリシス分析
  • 5つの根本原因分析による事業の問題の重要な調査と関連ソリューション

第4章 後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2020年~2030年)

  • 市場の概要
  • 成長と収益の分析:2021年対2030年
  • 市場セグメンテーション
    • デスモプレシン

第5章 後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2020年~2030年)

  • 市場の概要
  • 成長と収益の分析:2021年対2030年
  • 市場セグメンテーション
    • 血栓安定薬/抗線溶薬
    • その他

第6章 後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2020年~2030年)

  • 市場の概要
  • 成長と収益の分析:2021年対2030年
  • 市場セグメンテーション
    • 経口
    • 注射
    • その他

第7章 後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2020年~2030年)

  • 市場の概要
  • 成長と収益の分析:2021年対2030年
  • 市場セグメンテーション
    • 病院
    • 診療所
    • その他

第8章 北米の後天性フォンヴィレブランド病(AvWD)治療市場(2020年~2030年)

  • 市場の概要
  • 後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:地域別(2020年~2030年)
    • 北米

第9章 英国・欧州連合の後天性フォンヴィレブランド病(AvWD)治療市場(2020年~2030年)

  • 市場の概要
  • 後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:地域別(2020年~2030年)
    • 英国・欧州連合

第10章 アジア太平洋の後天性フォンヴィレブランド病(AvWD)治療市場の買収(2020年~2030年)

  • 市場の概要
  • 後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:地域別(2020年~2030年)
    • アジア太平洋

第11章 ラテンアメリカの後天性フォンヴィレブランド病(AvWD)治療市場(2020年~2030年)

  • 市場の概要
  • 後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:地域別(2020年~2030年)
    • ラテンアメリカ

第12章 中東・アフリカの後天性フォンヴィレブランド病(AvWD)治療市場(2020年~2030年)

  • 市場の概要
  • 後天性フォンヴィレブランド病(AvWD)治療市場:治療タイプ別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:補充療法別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医薬品投与経路別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:医療環境別(2020年~2030年)
  • 後天性フォンヴィレブランド病(AvWD)治療市場:地域別(2020年~2030年)
    • 中東・アフリカ

第13章 企業プロファイル

  • Baxter Healthcare Corporation
  • Biogen
  • Pfizer
  • F. HOFFMAN LA ROCHE
  • Sanofi
  • Ferring Pharmaceuticals
  • Genentech, Inc.
  • Bristol Myers Squibb
  • Novo Nordisk
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical
  • CSL Behring
  • Bayer AG
図表

List of Tables

  • TABLE 1 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 2 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 3 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 4 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 5 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 6 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 7 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 8 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 9 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 10 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 11 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 12 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 13 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 14 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 15 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 16 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 17 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 18 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 19 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 20 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 21 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 22 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 23 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 24 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 25 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 26 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 27 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 28 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 29 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 30 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 31 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 32 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 33 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 34 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 35 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 36 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 37 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 38 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 39 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 40 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 41 France Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 42 France Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 43 France Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 44 France Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 45 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 46 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 47 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 48 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 49 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 50 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 51 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 52 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 53 China Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 54 China Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 55 China Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 56 China Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 57 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 58 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 59 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 60 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 61 India Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 62 India Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 63 India Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 64 India Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 65 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 66 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 67 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 68 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 69 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 70 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 71 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 72 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 73 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 74 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 75 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 76 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 77 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 78 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 79 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 80 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 81 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 82 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 83 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 84 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 85 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 86 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 87 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 88 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 89 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 90 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 91 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 92 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 93 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 94 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 95 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 96 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 97 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 98 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 99 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 100 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
  • TABLE 101 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
  • TABLE 102 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
  • TABLE 103 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
  • TABLE 104 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Acquired von Willebrand Disease (AvWD) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Acquired von Willebrand Disease (AvWD) Treatment Market: Quality Assurance
  • FIG. 5 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021
  • FIG. 6 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021
  • FIG. 7 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021
  • FIG. 8 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021
  • FIG. 9 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Geography, 2021
  • FIG. 10 Market Geographical Opportunity Matrix - Global Acquired von Willebrand Disease (AvWD) Treatment Market, 2021
  • FIG. 11 Market Positioning of Key Acquired von Willebrand Disease (AvWD) Treatment Market Players, 2021
  • FIG. 12 Global Acquired von Willebrand Disease (AvWD) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 13 Porters Five Force Model - Current, Midterm and Long Term Perspective
  • FIG. 14 See Saw Analysis
  • FIG. 15 PETEL Analysis
  • FIG. 16 Key Buying Criteria: Current and Long-Term Perspective
  • FIG. 17 Global Acquired von Willebrand Disease (AvWD) Treatment Market, Scenario Analysis, 2020 to 2030 (US$ Million)
  • FIG. 18 Heptalysis Analysis: Global Acquired von Willebrand Disease (AvWD) Treatment Market
  • FIG. 19 Five Whys Analysis
  • FIG. 20 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021 Vs 2030, %
  • FIG. 21 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021 Vs 2030, %
  • FIG. 22 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021 Vs 2030, %
  • FIG. 23 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021 Vs 2030, %
  • FIG. 24 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Canada Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 UK Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Germany Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Spain Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Italy Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 France Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 32 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 33 China Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 34 Japan Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 35 India Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 36 Australia Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 37 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 38 Rest of Asia Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 39 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 40 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 41 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 42 GCC Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 43 Africa Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 44 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 139288-08-22

Acquired von Willebrand syndrome is a highly heterogeneous bleeding disorder, usually displays mild to moderate hemorrhagic symptoms that may at times be severe too. Many a time the severity increases post-surgery. AvWS is considered as a rare disorder, however, the actual prevalence is not as rare. In case the laboratory findings diagnoses vWD in a patient with no family history, AvWD associated conditions is usually explored. The acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of 2022 to 2030. 

Diagnosis Remains as The Largest Challenge

AvWD screening becomes crucial in patients with onco-hematologic disorders, patients who experienced unexplained bleeding, or before undergoing any invasive procedure. The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For example, it has been reported up to 20% of malignancies, and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. The diagnostic complexity and milder form of AvWS without symptoms make it difficult to finalize on the actual prevalence rate of AvWD. 

Increasing Support of Governments Led by Increasing Awareness of AvWS

The demand for the AvWD treatment market has increased as governments across the globe have become increasingly aware of the von Willebrand syndrome and its associated treatment. The treatment for this condition varies across countries. Hpwever, one of the significant driver impacting the market revenues is rising prevalence of bleeding disorders especially acquired bleeding disorders. Von Willebrand disease is a fairly prevalent bleeding disorder, according to the World Federation of Hemophilia. Von Willebrand disease is caused by a deficiency in the protein known as the Von Willebrand factor, which is present in the blood. 

Desmopressin records the highest revenues

In the year 2021, Desmopressin recorded the highest revenues in comparison to the other drugs. Desmopressin remains as the first line therapy for AvWD and is proven to be efficient for patients with mild symptoms. Easy accessibility of Desmopressin across the globe and availability of Desmopressin through different routes of drug administration such as injection, tablet and intranasal spray remains as the key driver for the dominance of this market segment. 

Injections Remained as Dominant Form Among Route of Drug Administration

In the year 2021, Injection as a mode of AvWD drug administration dominated the market segment with revenues of about $ 20,880 thousand. Major AvWD treatment drugs are administered through injections and infusions. Primary drug Desmopressin is widely administered through injections, similarly replacement therapies are also administered through this route. Injections respond very quickly during emergency and are very effective mode of drug administration. Therefore, the market is also expected to grow at the fastest pace during the forecast period. 

North America Dominates In terms of Market Revenues

North America was observed as the largest market for AvWD treatment in 2021. North America dominated the market due to its aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. Asia Pacific was observed as the attractive market for AvWS treatment due to its emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis. The key players in the acquired AvWS treatment market are Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA, and others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Acquired von Willebrand Disease (AvWD) Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Acquired von Willebrand Disease (AvWD) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

  • Treatment Type
  • Desmopressin
  • Replacement Therapy
  • Clot-stabilizing Medications/anti-fibrinolytic medications
  • Others
  • Route of Drug Administration
  • Oral
  • Injection
  • Others
  • Healthcare Settings
  • Hospitals
  • Clinics
  • Others
  •  Region Segment (2020-2030; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa
  • Global Impact of Covid-19 Segment (2020-2021; US$ Million )
  • Pre Covid-19 situation
  • Post Covid-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Acquired von Willebrand Disease (AvWD) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Acquired von Willebrand Disease (AvWD) Treatment market?
  • Which is the largest regional market for Acquired von Willebrand Disease (AvWD) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Acquired von Willebrand Disease (AvWD) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Acquired von Willebrand Disease (AvWD) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Acquired von Willebrand Disease (AvWD) Treatment Market
  • 2.2. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021 (US$ Million)
  • 2.3. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021 (US$ Million)
  • 2.4. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021 (US$ Million)
  • 2.5. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021 (US$ Million)
  • 2.6. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Geography, 2021 (US$ Million)
  • 2.7. Impact of Covid 19
  • 2.8. Attractive Investment Proposition by Geography, 2021
  • 2.9. Competitive Analysis
    • 2.9.1. Market Positioning of Key Acquired von Willebrand Disease (AvWD) Treatment Market Vendors
    • 2.9.2. Strategies Adopted by Acquired von Willebrand Disease (AvWD) Treatment Market Vendors
    • 2.9.3. Key Industry Strategies
    • 2.9.4. Tier Analysis 2021 Versus 2030
  • 2.10. Key Buying Criteria
  • 2.11. Key Case Reports
  • 2.12. Scenario Analysis
    • 2.12.1. Optimistic estimates and analysis
    • 2.12.2. Realistic estimates and analysis
    • 2.12.3. Pessimistic estimates and analysis
  • 2.13. Market Profiling
  • 2.14. Sales and Marketing Plan
  • 2.15. Top Market Conclusions
  • 2.16. Strategic Recommendations

3. Acquired von Willebrand Disease (AvWD) Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Acquired von Willebrand Disease (AvWD) Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape
  • 3.8. Heptalysis Analysis
  • 3.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions

4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Desmopressin

5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Clot-stabilizing Medications/anti-fibrinolytic medications
    • 5.3.2. Others

6. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Oral
    • 6.3.2. Injection
    • 6.3.3. Others

7. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Others

8. North America Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
  • 8.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
  • 8.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
  • 8.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
  • 8.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.6.1.North America
      • 8.6.1.1. U.S.
        • 8.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 8.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 8.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 8.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 8.6.1.2. Canada
        • 8.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 8.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 8.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 8.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 8.6.1.3. Rest of North America
        • 8.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 8.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 8.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 8.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)

9. UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
  • 9.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
  • 9.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
  • 9.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
  • 9.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.6.1.UK and European Union
      • 9.6.1.1. UK
        • 9.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 9.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 9.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 9.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 9.6.1.2. Germany
        • 9.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 9.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 9.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 9.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 9.6.1.3. Spain
        • 9.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 9.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 9.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 9.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 9.6.1.4. Italy
        • 9.6.1.4.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 9.6.1.4.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 9.6.1.4.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 9.6.1.4.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 9.6.1.5. France
        • 9.6.1.5.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 9.6.1.5.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 9.6.1.5.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 9.6.1.5.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 9.6.1.6. Rest of Europe
        • 9.6.1.6.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 9.6.1.6.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 9.6.1.6.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 9.6.1.6.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)

10. Asia Pacific Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
  • 10.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
  • 10.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
  • 10.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
  • 10.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.6.1.Asia Pacific
      • 10.6.1.1. China
        • 10.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 10.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 10.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 10.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 10.6.1.2. Japan
        • 10.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 10.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 10.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 10.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 10.6.1.3. India
        • 10.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 10.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 10.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 10.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 10.6.1.4. Australia
        • 10.6.1.4.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 10.6.1.4.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 10.6.1.4.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 10.6.1.4.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 10.6.1.5. South Korea
        • 10.6.1.5.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 10.6.1.5.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 10.6.1.5.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 10.6.1.5.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 10.6.1.6. Rest of Asia Pacific
        • 10.6.1.6.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 10.6.1.6.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 10.6.1.6.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 10.6.1.6.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)

11. Latin America Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
  • 11.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
  • 11.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
  • 11.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
  • 11.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 11.6.1.Latin America
      • 11.6.1.1. Brazil
        • 11.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 11.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 11.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 11.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 11.6.1.2. Mexico
        • 11.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 11.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 11.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 11.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 11.6.1.3. Rest of Latin America
        • 11.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 11.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 11.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 11.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)

12. Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)

  • 12.1. Market Overview
  • 12.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
  • 12.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
  • 12.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
  • 12.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
  • 12.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 12.6.1.Middle East and Africa
      • 12.6.1.1. GCC
        • 12.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 12.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 12.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 12.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 12.6.1.2. Africa
        • 12.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 12.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 12.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 12.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
      • 12.6.1.3. Rest of Middle East and Africa
        • 12.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
        • 12.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
        • 12.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
        • 12.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)

13. Company Profile

  • 13.1. Baxter Healthcare Corporation
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Biogen
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Pfizer
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. F. HOFFMAN LA ROCHE
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Sanofi
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Ferring Pharmaceuticals
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Genentech, Inc.
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Bristol Myers Squibb
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Novo Nordisk
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. GlaxoSmithKline plc
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. Takeda Pharmaceutical
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. CSL Behring
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. Bayer AG
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives